Can 18F-FDG-PET response during radiotherapy be used as a predictive factor for the outcome of head and neck cancer patients?

Nuclear Medicine Communications

Volumn 31, Issue 6, 2010, Pages 495-501

  Farrag, Ashraf ^a   Ceulemans, Gaëtane ^a   Voordeckers, Mia ^a   Everaert, Hendrik ^a   Storme, Guy ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

FDG PET; Head and neck cancer; Helical tomotherapy; Predictive factor; Standardized uptake values

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HEAD AND NECK CANCER; HUMAN; MALE; MEDICAL INFORMATION; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; TOMOTHERAPY; TREATMENT OUTCOME; AGED; HEAD AND NECK TUMOR; METABOLISM; MIDDLE AGED; SCINTISCANNING; SURVIVAL; TIME; TRANSPORT AT THE CELLULAR LEVEL;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77951764658     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283334e2b     Document Type: Article

References (38)

1. McGowan KM, Long SD, Pekala PH. Glucose transporter gene expression: regulation of transcription and mRNA stability. Pharmacol Ther 1995; 66:465-505.
2. Wahl RL. Targeting glucose transporters for tumor imaging: sweat idea, sour result. J Nucl Med 1996; 37:1038-1041.
3. Phelps ME. Positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci 2000; 97:9226-9233.
4. Salesiotis AN, Cullen KJ. Molecular markers predictive of response and prognosis in the patient with advanced squamous cell carcinoma of the head and neck: evolution of a model beyond TNM staging. Curr Opin Oncol 2000; 12:29-39.
5. Minn H, Clavo AC, Grenman R, Wahl R. In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous cell carcinoma of the head and neck. J Nucl Med 1995; 36:252-258.
6. Haberkorn U, Strauss LG, Reisser C, Haag D, Dimitrakopoulou A, Ziegler S. Glucose uptake, perfusion, and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry. J Nucl Med 1991; 32:1548-1555.
7. Price P, Jones T. Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? Eur J Cancer 1995; 31A:1924-1927.
8. Brun E, Kjellen E, Tennvall J, Ohlsson T, Sandell A, Perfekt R, et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck 2002; 24:127-135.
9. Schelling M, Avril N, Nährig W, Kuhn W, Römer W, Sattler D, et al. Positron emission tomography using 18F fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Cin Oncol 2000; 18:1689-1695.
10. Schulte M, Brecht Krauss D, Werner M, Hartwig E, Sarkar MR, Keppler P, et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG-PET. J Nucl Med 1999; 40:1637-1643.
11. Schwarz JK, Lin LL, Siegel BA, Miller TR, Grigsby PW. 18F-fluorodeoxyglucose positron emission tomography evaluation of early metabolic response during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 2008; 72:1502-1507.
12. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005; 16:1514-1523.
13. Decoster L, Schallier D, Everaert H, Nieboer K, Meysman M, Neyns B, et al. Complete metabolic tumor response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC). Lung Cancer 2008; 62:55-61.
14. Brock C, Young H, O'Reilly SM, Matthews J, Osman S, Evans H, et al. Early evaluation of tumor metabolic response using 18F-fluorodeoxyglucose and positron emission tomography: a pilot study after the phase 11 chemotherapy schedule for temozolamide in recurrent high grade gliomas. Br J Cancer 2000; 82:608-615.
15. Greene FL, Page DL, Fleming I, Fritz A. AJCC cancer staging manual. New York: Springer-Verlage; 2002.
16. Fiorino C, Dell'Oca I, Pierelli A, Broggi S, Cattaneo GM, Chiara A, et al. Simultaneous integrated boost (SIB) for nasopharynx cancer with helical tomotherapy. A planning study. Strahlenther Onkol 2007; 183:497-505.
17. Gregoire V, Coche E, Cosnard G, Hamoir M, Reychler H. Selection and delineation of lymph node target volumes in head and neck conformal radiotherapy. Proposal for standardizing terminology and procedure based on the surgical experience. Radiother Oncol 2000; 56:135-150.
18. Voordeckers M, Everaert H, Tournel K, Verellen D, Baron I, Van Esch G, et al. Longitudinal assessment of parotid function in patients receiving tomotherapy for head and neck cancer. Strahlenther Onkol 2008; 8:400-405.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
20. Wennerberg J. Predicting response to therapy of squamous cell carcinoma of the head and neck. Anticancer Res 1996; 16:2389-2396.
21. Pandit N, Gonen M, Krug L, Larson SM. Prognostic value of (18F) FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging 2003; 30:78-84.
22. Karasawa K, Kaminuma T, Chang T, Hanyu N, Kuga G, Maesawa N. Prognostic significance of high SUV-max of the pretreatment FDG-PET scan in the conformal treatment of solitary non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2008; 72:S457-S458.
23. Rizk N, Downey R, Akhurst T, Gonen M, Bains M, Larson S, et al. Preoperative 18(F)-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection. Ann Thorac Surg 2006; 81:1076-1081.
24. Xue F, Lin L, Dehdashti F, Miller T, Siegel B, Grigsby P. F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy. Gynecol Oncol 2006; 101:147-151.
25. Dimitakoploulou-Strauss A, Strauss LG, Rudi J. PET-FDG as predictor of therapy response in patients with colorectal cancer. Q J Nucl Med 2003; 47:8-13.
26. Allal AS, Dulguerov P, Allaoua M, Haenggeli C, El Ghazi E, LehmannW, et al. Standardized uptake value of 2-(18 F) fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 2002; 20:1398-1404.
27. Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W, Dulguerov P. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-(18F) fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys 2004; 59:1295-1300.
28. Minn H, Lapela M, Klemi PJ, Grenman R, Leskinen S, Lindholm P, et al. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med 1997; 38:1907-1911.
29. Wong RJ, Lin DT, Schoder H, Patel SC, Gonen M, Wolden S, et al. Diagnostic and prognostic value of (18) fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol 2002; 20:4199-4208.
30. Lee S, Nam S, Im K, Kim JS, Choi EK, Ahn SD, et al. Prediction of prognosis using standardized uptake value of 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography for nasopharyngeal carcinomas. Radiother Oncol 2008; 87:211-216.
31. Hoekstra CJ, Paglianiti I, Hoekstra OS, Smit EF, Postmus PE, Teule GJ, et al. Monitoring response to therapy in cancer using 18F-2-fluoro-2-deoxy-D- glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med 2000; 27:731-743.
32. Kubota R, Yamad S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J NucI Med 1992; 33:1972-1980.
33. Malide D, Davies-Hill TM, Levine M, Simpson I. Distinct localization of GLUT-1, -3, and -5 in human monocyte-derived macrophages: effect on cell activation. Am J Physiol Endocrinol Metab 1998; 274:516-526.
34. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after one cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002; 43:1018-1027.
35. Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K, et al. (18F) fluoro- 2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005; 106:1376-1381.
36. Goodman MD, Tarnoff M, Kain M, Slotman GJ. Interactions between outcomes and tumour response to preoperative cisplatin-sensitized radiotherapy in advanced head and neck cancer. Southern New Jersey Head and Neck Cancer Treatment Group. Am J Surg 1997; 174:527-531.
37. Wanebo H, Chougule P, Ready N, Safran H, Ackerley W, Koness RJ, et al. Surgical resection is necessary to maximize tumour control in function-preserving, aggressive chemoradiation protocols for advanced squamous cancer of the head and neck (stage III and IV). Ann Surg Oncol 2001; 8:644-650.
38. Szabo G, Kreidler J, Hollmann K, Kovacs A, Nemeth G, Nemeth Z, et al. Intra-arterial preoperative cytostatic treatment versus preoperative irradiation: a prospective, randomised study of lingual and sublingual carcinomas. Cancer 1999; 86:1381-1386.